Update
$Clene (CLNN.US)$ Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting 2 MINUTES AGO, 7:00 AM EDT VIA GLOBENEWSWIRE - Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline (hazard ratio: 0.431, p=0.0002) Average of 28% NfL reduction observed in an NfL responder subset (geometric mean ratio, change at Week 76 post-baseline: 0.72, p
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Trytosaveabit OP : Clene Inc.: More Than 650 Patient Years of Cnm-AU8 Treatment Exposure Without Any Identified Safety Signals
74043947 Trytosaveabit OP : Sounds bad lol
Trytosaveabit OP 74043947 : Hehehe!